For informational and research purposes only. Not medical advice. Content is aggregated from public sources. Always consult a qualified healthcare provider.
Healing & Recovery · Comparison

BPC-157 vs Oxytocin

A neutral, side-by-side comparison of two healing & recovery peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.

BPC-157Oxytocin
CategoryHealing & RecoveryHealing & Recovery
Also known asBody Protection Compound 157, PL 14736, Pentadecapeptide BPC 157OT, Pitocin, Syntocinon, trust hormone, bonding peptide
EvidencePreclinical onlyResearch-stage
Dosing range200mcg–1000mcg mcg, once or twice daily10–20IU–100–160IU IU, Intranasal 30–60 minutes pre-activity; 1–2x daily for wound healing or anti-inflammatory protocols
AdministrationSubcutaneous injection (most common), Intramuscular injection, Oral (reduced bioavailability — used for gut-specific protocols)Intranasal spray, Subcutaneous injection, Intravenous (clinical)
Key side effectsNausea (rare, typically at higher doses), Dizziness / lightheadedness shortly after injection (uncommon, anecdotal), Injection site redness or irritation, Human safety profile is not established — no controlled human trialsNausea, Headache, Transient hypotension, Hyponatremia (high IV doses — water retention effect)
Cited sources6 references2 references

Key differences

  • Evidence level differs: BPC-157 is preclinical only, while Oxytocin is research-stage.
  • Administration: BPC-157 — Subcutaneous injection (most common), Intramuscular injection, Oral (reduced bioavailability — used for gut-specific protocols); Oxytocin — Intranasal spray, Subcutaneous injection, Intravenous (clinical).
  • Dosing units differ: BPC-157 is dosed in mcg, Oxytocin in IU — they operate at different scales.
  • Frequency: BPC-157 is typically once or twice daily; Oxytocin is Intranasal 30–60 minutes pre-activity; 1–2x daily for wound healing or anti-inflammatory protocols.
  • Research depth: this profile cites 6 sources for BPC-157 vs 2 for Oxytocin.

How each works

BPC-157

Preclinical rodent and in-vitro studies — predominantly from the Sikiric group in Zagreb, with mechanistic angiogenesis work from Pang's group in Taiwan — report accelerated healing of tendon, ligament, muscle, and gut tissue. Proposed mechanisms include modulation of the nitric oxide (NO) system, promotion of angiogenesis via the VEGFR2–Akt–eNOS pathway, upregulation of growth factor signaling, and effects along the gut–brain axis. Despite a large and internally consistent animal literature, BPC-157 has no completed human clinical efficacy trials and is an unapproved drug.

Oxytocin

Oxytocin binds oxytocin receptors (OTR) throughout the brain and periphery, producing prosocial, anxiolytic, and anti-inflammatory effects. The landmark 2005 Kosfeld et al. Nature study demonstrated that intranasal oxytocin increased trust in humans in economic game paradigms. Peripheral effects include acceleration of wound healing, modulation of inflammatory cytokines, and parasympathetic nervous system activation.

Read the full BPC-157 profileRead the full Oxytocin profile

This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.